




Searching News Database: Halozyme Therapeutics
HSMN NewsFeed - 26 Apr 2022
Halozyme Commences Tender Offer for All Outstanding Shares of Common Stock of Antares Pharma
Halozyme Commences Tender Offer for All Outstanding Shares of Common Stock of Antares Pharma
HSMN NewsFeed - 13 Apr 2022
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
HSMN NewsFeed - 4 Nov 2019
Halozyme Announces Actions To Focus Strategy On ENHANZE(R) Drug Delivery Technology
Halozyme Announces Actions To Focus Strategy On ENHANZE(R) Drug Delivery Technology
HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
HSMN NewsFeed - 18 Dec 2018
Erasca Launches with $42 Million Series A Financing to Support Bold Mission of Erasing Cancer
Erasca Launches with $42 Million Series A Financing to Support Bold Mission of Erasing Cancer
HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
HSMN NewsFeed - 5 Sep 2018
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
HSMN NewsFeed - 28 Feb 2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
HSMN NewsFeed - 3 Jan 2018
Denovo Biopharma Opens New R&D Center, Names Chief Medical Officer and Chief Financial Officer
Denovo Biopharma Opens New R&D Center, Names Chief Medical Officer and Chief Financial Officer
HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
HSMN NewsFeed - 30 Jan 2017
AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer
AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer
HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
HSMN NewsFeed - 6 Sep 2011
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
HSMN NewsFeed - 5 Oct 2009
Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration
Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration
HSMN NewsFeed - 27 Jul 2009
Halozyme Therapeutics Appoints Jonathan Leff, M.D. as Vice President, Chief Medical Officer
Halozyme Therapeutics Appoints Jonathan Leff, M.D. as Vice President, Chief Medical Officer
HSMN NewsFeed - 25 Feb 2009
ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer
ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer
HSMN NewsFeed - 23 Sep 2008
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
HSMN NewsFeed - 2 Sep 2008
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
HSMN NewsFeed - 13 Nov 2007
Halozyme Therapeutics Names Matthew R. Hooper Vice President, General Counsel
Halozyme Therapeutics Names Matthew R. Hooper Vice President, General Counsel
HSMN NewsFeed - 31 May 2007
Halozyme Therapeutics Announces Closing of $32.1 Million Private Financing
Halozyme Therapeutics Announces Closing of $32.1 Million Private Financing
HSMN NewsFeed - 16 May 2007
Halozyme Therapeutics Names Randal J. Kirk and Kathryn E. Falberg to Board of Directors
Halozyme Therapeutics Names Randal J. Kirk and Kathryn E. Falberg to Board of Directors
HSMN NewsFeed - 8 Nov 2006
Halozyme Therapeutics Names William Fallon Vice President, Manufacturing & Operations
Halozyme Therapeutics Names William Fallon Vice President, Manufacturing & Operations
HSMN NewsFeed - 27 Jun 2006
Halozyme and Baxter Announce Availability of Hylenex for Subcutaneous Delivery of Medications and Fluids
Halozyme and Baxter Announce Availability of Hylenex for Subcutaneous Delivery of Medications and Fluids
HSMN NewsFeed - 23 May 2006
Halozyme Therapeutics Announces FDA 510(k) Clearance for MediCult's SynVitro Cumulase Product
Halozyme Therapeutics Announces FDA 510(k) Clearance for MediCult's SynVitro Cumulase Product
HSMN NewsFeed - 2 Feb 2006
Halozyme Therapeutics Initiates Clinical Trial of Subcutaneous Morphine With Hylenex
Halozyme Therapeutics Initiates Clinical Trial of Subcutaneous Morphine With Hylenex
HSMN NewsFeed - 24 Jan 2006
Halozyme Therapeutics Completes Enrollment of INFUSE-LR, a Hylenex Clinical Trial of Subcutaneous Hydration
Halozyme Therapeutics Completes Enrollment of INFUSE-LR, a Hylenex Clinical Trial of Subcutaneous Hydration
Additional items found! 11

Members Archive contains
11 additional stories matching:
Halozyme Therapeutics
(Password required)
Halozyme Therapeutics
(Password required)